FSLR
64
-6
MO
38
2
CAG
37
3
SNA
60
4
AMG
38
2
JPM
52
-3
VRSN
54
2
DE
50
2
VRTX
62
5
EBAY
50
-2
EXPE
72
8
SIG
57
7
ALLE
66
2
DTE
63
4
QRVO
56
4
SO
68
4
KMI
44
-9
WY
60
7
SRE
54
5
DLTR
27
3
FSLR
64
-6
MO
38
2
CAG
37
3
SNA
60
4
AMG
38
2
JPM
52
-3
VRSN
54
2
DE
50
2
VRTX
62
5
EBAY
50
-2
EXPE
72
8
SIG
57
7
ALLE
66
2
DTE
63
4
QRVO
56
4
SO
68
4
KMI
44
-9
WY
60
7
SRE
54
5
DLTR
27
3
Financhill
Back

C4 Therapeutics 10K Form

Sell
24

CCCC
C4 Therapeutics

Last Price:
6.32
Seasonality Move:
-34.49%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CCCC News And Ratings

See the #1 stock for the next 7 days that we like better than CCCC

CCCC Financial Statistics

Sales & Book Value

Annual Sales: $20.76M
Cash Flow: $-5.17M
Price / Cash Flow: 0
Annual Sales: $3.59
Price / Book: 1.81

Profitability

EPS (TTM): -1.90000
Net Income (TTM): $-107.87M
Gross Margin: --
Return on Equity: -44.9%
Return on Assets: -28.94%

C4 Therapeutics Earnings Forecast

Key C4 Therapeutics Financial Ratios

  • The Research & Development expenses have been 567.09% of Revenue.
  • The Interest Expense is -1.04% of Operating Income.
  • The Net Earning history of CCCC is -638.34% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

C4 Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CCCC
CUSIP: 12529R
Website: c4therapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.09
Quick Ratio: 4.89

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CCCC Technical Analysis vs Fundamental Analysis

Sell
24
C4 Therapeutics (CCCC) is a Sell

Is C4 Therapeutics a Buy or a Sell?

  • C4 Therapeutics stock is rated a Sell
    The current C4 Therapeutics [CCCC] share price is $6.44. The Score for CCCC is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.